Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of pharmacogenetic polymorphisms on rivaroxaban in elderly atrial fibrillation patients
ChiCTR2300074934Phase 4Not yet recruiting
- Sponsor
- Jinhua Hospital of Zhejiang University
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rivaroxaban in Atrial fibrillation (AFib), sponsored by Jinhua Hospital of Zhejiang University. Primary endpoints: bleeding events, thrombotic events and 2 more. Planned start Aug 2023; status: not yet recruiting.
02
Drugs
rivaroxaban
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on ChiCTR2300074934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300074934.